在临床肿瘤学的领域中,最近前列腺癌的资料较多。日本人前列腺癌发病率虽然很低,但其患病增长率在男性恶性肿瘤中最高。潜伏癌的比例与西欧各国之间无差异。在诊断方面,生物化学测定法是较敏感的早期诊断法。在治疗上已从单一的内分泌疗法转向手术、放疗、化疗等多种疗法。本文将对前列腺癌的诊疗进展予以叙述。1.流行病学动向曾有人指出前列腺癌的发病率有人种差异。据国际癌研究机构报道五大洲癌患病率,每10万人中日本患病率2.7(宫城县)～2.8(罔山县);美国白人40.4,美国沙布拉西克地区黑人77.0,日本人患病率最低。前列腺癌的死亡率(每10万人中相同年龄组在不 In the field of clinical oncology, there is more information on prostate cancer recently. Although the incidence of prostate cancer in Japan is very low, its prevalence is highest among male malignancies. There is no difference between the proportion of latent cancer and Western European countries. In terms of diagnosis, biochemical assays are more sensitive early diagnostics. In the treatment has been turned from a single endocrine therapy surgery, radiotherapy, chemotherapy and other therapies. This article will describe the progress of diagnosis and treatment of prostate cancer. 1. Epidemiological trends It has been pointed out that there are racial differences in the incidence of prostate cancer. According to the International Agency for Research on Cancer report on the prevalence of cancer in five continents, the prevalence of Japanese in every 100,000 population is 2.7 (Miyagi Prefecture) ~ 2.8 (Mt. Fujishan); 40.4 for the U.S. White, 77.0 for the Black, The lowest prevalence in Japan. Prostate cancer mortality (the same age group for every 100,000 people is not